Status:
TERMINATED
Immunobiology of Cancer
Lead Sponsor:
Stanford University
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
To learn whether or not an Interferon defect in cell signaling, recently discovered in immune cells from melanoma patients as well as breast cancer patients, is common to all cancers.
Detailed Description
BACKGROUND We have previously demonstrated that tumor-specific T cells could be identified in \>50% of patients with metastatic melanoma and these cells appeared to be rendered anergic in vivo \[Natu...
Eligibility Criteria
Inclusion
- Participants who have cancer or participants who do not have cancer and/or an autoimmune disorder and are age 18 or over.
Exclusion
- Participants who have an autoimmune disorder and/or are under the age of 18 years.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00767533
Start Date
October 1 2008
End Date
October 1 2011
Last Update
July 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305